315 results
Page 8 of 16
8-K
EX-1.1
ib67 0oqb
16 Mar 12
Discovery Labs Prices $45.0 Million Public Offering of
12:00am
424B5
h8mjudfkwuqcfu2sw
15 Mar 12
Prospectus supplement for primary offering
12:00am
8-K
plmota44i82fb
7 Mar 12
Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) for Prevention of Respiratory Distress Syndrome
12:00am
424B5
l5ls6icnbi3aqbar
15 Dec 11
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
shhy52
14 Dec 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
3ngocc6 0zp
3 Aug 11
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
2pglznfkqmmusj9
22 Jul 11
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.1
zkn2bgkzb0zyb
18 Jul 11
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
wth whqnm
11 May 11
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
04io31f
22 Mar 11
Results of Operations and Financial Condition
12:00am
424B5
s13ztdfr hyxqp
17 Feb 11
Prospectus supplement for primary offering
12:00am
8-K
EX-1.1
a9b8qs7dx0cdzzk
16 Feb 11
Discovery Labs Prices $23.5 Million Public Offering of
12:00am
424B5
y8g5aseqvnwfjk hzud
15 Feb 11
Prospectus supplement for primary offering
12:00am